News
BMEA
0.5668
-3.51%
-0.0206
Weekly Report: what happened at BMEA last week (1026-1030)?
Weekly Report · 5d ago
Piper Sandler Reaffirms Their Buy Rating on Biomea Fusion (BMEA)
TipRanks · 10/30 12:06
Weekly Report: what happened at BMEA last week (1019-1023)?
Weekly Report · 10/26 09:08
Weekly Report: what happened at BMEA last week (1012-1016)?
Weekly Report · 10/19 09:08
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Demant (OtherWILLF) and Biomea Fusion (BMEA)
TipRanks · 10/15 10:50
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/14 17:06
Biomea Fusion Price Target Maintained With a $7.00/Share by Citizens
Dow Jones · 10/14 13:00
Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Target
Benzinga · 10/14 12:51
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/14 12:06
State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 10/14 12:02
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Alnylam Pharma (ALNY) and Kura Oncology (KURA)
TipRanks · 10/14 11:10
Biomea Fusion Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 10/14 10:35
Biomea Fusion Reports Phase 1 Results for BMF-650
TipRanks · 10/14 10:32
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $4 Price Target
Benzinga · 10/14 10:21
Why Enovix Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/14 08:51
What’s Going On With Biomea Fusion (BMEA) Stock After Hours?
Benzinga · 10/14 06:12
Biomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares Fall
NASDAQ · 10/14 02:34
Closing Bell Movers: Liquidia jumps on settlement with United Therapeutics
TipRanks · 10/13 23:50
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/13 21:06
Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding
Benzinga · 10/13 20:29
More
Webull provides a variety of real-time BMEA stock news. You can receive the latest news about Biomea Fusion, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BMEA
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies, including icovamenib and BMF-650, for diabetes and obesity, with research activities focused on the biology of metabolic diseases. Its covalent small molecule drug is a synthetic compound that forms a permanent bond with its target protein. The Company’s clinical candidate, icovamenib, is an investigational oral small molecule that reversibly downmodulates menin, a transcriptional regulator involved in beta-cell biology. Its Phase 2 clinical development includes type 1 and type 2 diabetes, obesity, and combination with GLP-1 receptor agonist therapies. The Company’s second product candidate, BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for the treatment of diabetes and obesity.